Recent News

• 09.11.2025 - Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance
• 09.02.2025 - Top U.S. Honor Roll Hospital Expands Use of INSPIRA™ ART100 System to Lung Transplant Procedures
• 08.23.2025 - Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market
• 08.19.2025 - Inspira Secures $27 Million Government Binding Purchase Order for ART100 Systems with Full Payment in 2025
• 08.07.2025 - Inspira Clarifies Routine Nature of Registration Statement on Form F-3 Filing Performed Every Three Years
• 07.31.2025 - Inspira Activates U.S. Based Consulting Firm to Execute Transformational Initiatives
• 07.18.2025 - Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement

Recent Filings

• 09.11.2025 - EX-99.1 EX-99.1
• 09.11.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.10.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 09.02.2025 - EX-99.1 EX-99.1
• 09.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.22.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.22.2025 - EX-99.1 EX-99.1
• 08.19.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.19.2025 - EX-99.1 EX-99.1
• 08.06.2025 - F-3 Registration statement by foreign private issuers